Cover Image
市場調查報告書

多發性骨髓瘤(柯勒病):開發中產品分析

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229718
出版日期 內容資訊 英文 1031 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤(柯勒病):開發中產品分析 Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 1031 Pages
簡介

所謂多發性骨髓瘤是惡性漿細胞在骨髓內部增殖,並產生異常大量特殊蛋白質的癌症。其病因至今不明。高齡者是主要發病者。主要症狀有貧血症及出血、神經損傷、皮膚病變、骨頭壓痛、疼痛、腎功能衰竭等。主要治療方法有化療及放射療法、免疫抑制劑、外科手術等。

本報告提供全球各國治療多發性骨髓瘤(柯勒病)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

多發性骨髓瘤概要

治療藥的開發

  • 多發性骨髓瘤開發中產品:概要
  • 多發性骨髓瘤開發中產品:比較分析

各企業開發中的多發性骨髓瘤治療藥

大學/研究機關研究中的多發性骨髓瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

多發性骨髓瘤治療藥:開發中的產品一覽(各企業)

多發性骨髓瘤治療藥:研究中的產品一覽(各大學/研究機關)

多發性骨髓瘤開發治療藥的企業

多發性骨髓瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

多發性骨髓瘤治療藥:暫停開發的產品

多發性骨髓瘤治療藥:中止開發的產品

多發性骨髓瘤相關產品的開發里程碑

  • 最新消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8160IDB

Summary

Global Markets Direct's, 'Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016', provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
  • The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Myeloma (Kahler Disease) Overview
  • Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Pipeline Products Glance
  • Multiple Myeloma (Kahler Disease) - Products under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH , H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APO-T B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by BioInvent International AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ConverGene, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curis, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science s.r.l., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology, LLC., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunocore Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancer Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kezar Life Sciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Medivation, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co., Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Midatech Pharma US Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed S.p.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar, S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Progenra, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quest PharmaTech Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx, S.L., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rodos BioTarget GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selvita S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TG Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Verastem, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top